Keywords: Geriatrics; DMARDs; Rheumatology; Rheumatoid arthritis; Tofacitinib; Apremilast;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Tofacitinib; Healthy volunteers; T cells; Natural killer cells; Interferon-γ; Cytotoxicity;
Keywords: Tofacitinib; Immunology; Immune function; Lymphoma; Toxicology; Immunomodulation;
Keywords: Tofacitinib; Opportunistic infections; Cytomegalovirus retinitis;
Keywords: Janus kinase; Tofacitinib; JAK; Transplantation;
Keywords: Malignancy; Rheumatoid arthritis; Jak inhibitors; Tofacitinib; Lymphoma; Lung cancer;
Keywords: alopecia areata; atopic dermatitis; baricitinib; dermatology; graft versus host disease; JAK inhibitors; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AE; adverse event; CANDLE; chronic atypical neutrophilic de
Keywords: punch sticking; compression; pressure; bonding strength; surface area; plastic deformation; 1/C; KL plasticity parameter; ε; porosity; εc; critical porosity; Ï; tensile strength; CEL; celecoxib; D3,2; Sauter mean diameter; ER; elastic recovery; GLY; gl
Keywords: Tofacitinib; Psoriasis; Lipoproteins; Lipid levels; Lipid metabolism; HDL function; Cardiovascular risk;
Keywords: Interleukin 21; Pemphigus; Autoimmune disease; Target therapy; Tofacitinib; Monoclonal antibody
Keywords: Enfermedad inflamatoria intestinal; Enfermedad de Crohn; Colitis ulcerosa; Tratamiento; Inmunosupresores; Anti-TNF; Biosimilar; Vedolizumab; Tofacitinib; Células madre; Trasplante fecal; Inflammatory bowel disease; Crohn disease; Ulcerative colitis; Trea
Keywords: IL-17; IL-22 family; IL-23; inflammation; Janus kinase; keratinocyte; psoriasis; phosphorylated signal transducer and activator of transcription; TH17Â cell; tofacitinib; AMP; Antimicrobial peptide; DC; Dendritic cell; DEFB4A; Defensin beta 4a; FDR; False
Keywords: Biomarkers; Endoscopy; Mayo Score; Tofacitinib; AUC; area under the curve; CI; confidence interval; FCP; fecal calprotectin; ROC; receiver operating characteristic;
Keywords: atopic dermatitis; Janus kinase inhibitor; tofacitinib; AD; atopic dermatitis; IL; interleukin; JAK; Janus kinase; QoL; quality of life; SCORAD; Scoring of Atopic Dermatitis; STAT; signal transducer and activator of transcription; Th2; type 2 helper T-cel
Keywords: Tuberculosis; Host-directed therapy; Tofacitinib
Keywords: Psoriasis; Methotrexate; Cyclosporine; Acitretin; Apremilast; Tofacitinib; Mycophenolate mofetil;
Keywords: Janus kinase inhibitors; Small-molecule therapy; Tofacitinib; Inflammatory bowel disease; Ulcerative colitis; Crohn disease;
Keywords: Signal transduction; Rheumatoid arthritis; Inflammation; Kinase inhibitor; Tofacitinib; Kinase; Arthritis; Small molecule;
Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
Keywords: alopecia universalis; Janus kinase inhibition; tofacitinib; AA; alopecia areata; AT; alopecia totalis; AU; alopecia universalis; JAK; Janus kinase; IFN; interferon;
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Keywords: immune response; Janus kinase inhibitor; pneumococcal vaccine; T cell; tetanus toxoid; tofacitinib; CI; confidence interval; ELISA; enzyme-linked immunosorbant assay; GMFR; geometric mean fold rise; JAK; Janus kinase; LTE; long-term extension; OPA; opsono
Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment
Keywords: miRNA; Tofacitinib; JAK; STAT; Firefly Bioworks;
Emerging therapies for atopic dermatitis: JAK inhibitors
Keywords: atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib; CPK; creatine phosphokinase; Cr; creatinine; EASI; Eczema Area and Severity Index; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; STAT; signal
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
Keywords: Chronic myeloid leukemia; JAK inhibitor; BCR-ABL; Tofacitinib; Imatinib;
Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS
Keywords: JAK; Inhaled LPS rat model; Tofacitinib; Lung inflammation; BALF; STAT3; BALF; bronchoalveolar lavage fluid; JAK; janus kinase; LPS; lipopolysaccharide; pSTAT3; phosphorylated STAT3; STAT; signal transducers and activators of transcription; TLR; toll-like
JAK inhibitors in dermatology: The promise of a new drug class
Keywords: alopecia areata; atopic dermatitis; baricitinib; JAK inhibitor; JAK-STAT; psoriasis; ruxolitinib; tofacitinib; vitiligo; AA; alopecia areata; AD; atopic dermatitis; AT; alopecia totalis; AU; alopecia universalis; CANDLE; chronic atypical neutrophilic derm
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Keywords: JAK; Janus kinase; narrowband ultraviolet B; nbUVB; phototherapy; ruxolitinib; tofacitinib; vitiligo; BSA; body surface area; CXCL9; C-X-C motif chemokine ligand 9; ELISA; enzyme-linked immunosorbent assay; IFN-γ; interferon gamma; JAK; Janus kinase; nbU
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies
Keywords: Janus kinase; Latin America; Rheumatoid arthritis; Tofacitinib; Kinasas Janus; Latinoamérica; Artritis reumatoide; Tofacitinib;
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
Keywords: Asia; Janus kinase inhibitor; Tofacitinib; Plaque psoriasis; Efficacy; Safety;
Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma development
Keywords: Hibernoma; JAK inhibition; pSTAT; Sympathetic stimulation; Tofacitinib;
Impact of tofacitinib treatment on human B-cells in vitro and in vivo
Keywords: B-lymphocytes; Tofacitinib; Immune modulation; tsDMARDs; JAK inhibitors; Rheumatoid arthritis;
IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury
Keywords: ischemia-reperfusion; macrophage polarization; STAT6; tofacitinib;
Pharmacotherapy Pearls for the Geriatrician
Keywords: Geriatrics; DMARDs; Rheumatology; Tofacitinib;
Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats
Keywords: Adjuvant induced arthritis (AIA); Tofacitinib; Th1 cells; Pro-inflammatory cytokine IL-1β;
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice
Keywords: Tofacitinib; Atherosclerosis; Macrophage; Inflammation; Foam cell formation;
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
Keywords: Malignancies; Tofacitinib; JAK inhibitors; Biological disease-modifying antirheumatic drugs;
Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation
Keywords: Alkali burn; Corneal inflammation; Janus kinase inhibitor; Small molecule drug; Tofacitinib;
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
Keywords: cardiovascular outcomes; cardiovascular risk factors; major adverse cardiovascular events psoriasis; tofacitinib; BID; twice daily; BP; blood pressure; CV; cardiovascular; HbA1c; glycated hemoglobin; HDL; high-density lipoprotein; hsCRP; high-sensitivity
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Keywords: efficacy; Janus kinase inhibitor; long-term; psoriasis; randomized controlled trial; safety; tofacitinib; AE; adverse event; BID; twice daily; CI; confidence interval; HZ; herpes zoster; IR; incidence rate; LTE; long-term extension; NMSC; nonmelanoma skin
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases
Keywords: costs; Janus kinase inhibitor; real-world experience; rheumatoid arthritis; tofacitinib; treatment patterns;
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis
Keywords: disease-modifying antirheumatic drugs; rheumatoid arthritis; tofacitinib; tumor necrosis factor inhibitors;
Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib
Keywords: JAK3 activation mechanism; Kinetic mechanism; Sequential random; Tofacitinib; Time dependent inhibition; FERM domain; Band 4.1, Ezrin, Radixin, Moesin homology domain; DTT; dithiothreitol; Hepes; N-(2-hydroxyethyl) piperazine-Nâ²-2-ethanesulfonic acid; P
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Keywords: ALL; acute lymphocytic leukemia; AML; acute myelogenous leukemia; AS; activation segment; CS or C-spine; catalytic spine; CL; catalytic loop; HΦ or Φ; hydrophobic; IFN; interferon; IL; interleukin; JAK1/2; Janus kinases 1 and 2; MW; molecular weight; NS
Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions
Keywords: Janus-Kinase inhibitor; Tofacitinib; Oclacitinib; Aggression; Mice
Posicionamento sobre o uso de tofacitinibe no algoritmo do Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide
Keywords: Artrite reumatoide; Tratamento; Brasil; TofacitinibeRheumatoid arthritis; Treatment; Brazil; Tofacitinib
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
Keywords: cost-effectiveness; rheumatoid arthritis; South Korea; tofacitinib;
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
Keywords: Tofacitinib; CP-690,550; Crohn's Disease; Randomized Control Trial; AE; adverse event; ANC; absolute neutrophil count; CDAI; Crohn's Disease Activity Index; CI; confidence interval; CRP; C-reactive protein; HDL; high-density lipoprotein; IBDQ; Inflamm
Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis
Keywords: Janus kinase; rheumatoid arthritis; tofacitinib
Tofacitinib and Other Kinase Inhibitors in the Treatment of Psoriasis
Keywords: Psoriasis; Small molecules; Kinases; Tyrosine kinase; Janus kinase; Tofacitinib; RuxolitinibPsoriasis; Pequeñas moléculas; Cinasas; Tirosina cinasas; Janus cinasas; Tofacitinib; Ruxolitinib
Tofacitinib y otros inhibidores de las cinasas en el tratamiento de la psoriasis
Keywords: Psoriasis; Pequeñas moléculas; Cinasas; Tirosina cinasas; Janus cinasas; Tofacitinib; RuxolitinibPsoriasis; Small molecules; Kinases; Tyrosine kinase; Janus kinase; Tofacitinib; Ruxolitinib